Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus HICON.
DICYCLOMINE HYDROCHLORIDE vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
10-20 mg orally 3-4 times daily
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category A/B
Category C
Anticholinergic
Anticholinergic